- 1 day ago
In addition to presenting data at ESMO positioning its PD1 as potentially the standard of care in a new indication, Incyte thinks it has an important new drug in its CDK2 inhibitor
- 1 day ago
Bicycle Therapeutics CEO Kevin Lee highlights the company's data at the 2024 ESMO Congress
- 2 days ago
The founder of Entos Pharmaceuticals describes trying to design a delivery vehicle that's better than AAV and LNPs by harnessing fusogens
- 4 days ago
Merck KGaA's head of global R&D and CMO gives an overview of the company's programs and its appetite for business development
- 4 days ago
London's Epsilogen completed a £12.5 million Series B expansion this week to take its IgE based folate receptor alpha program into a phase 1b study
- 5 days ago
The Co-CEOs of Summit Therapeutics discuss the ivonescimab vs Keytruda data that was presented at the 2024 World Conference on Lung Cancer
- 6 days ago
Berlin based T-knife Therapeutics is carrying on the tradition of German leadership in TCR based technologies in oncology
- 6 days ago
Andreas Eckert, founder of Eckert & Ziegler, is an expert in radio isotopes and how they are used in medicine. A subsidiary, Pentixapharm, is about to be spun off into is own public company
- Sep 6
Travere's FILSPARI earned a conversion of its accelerated approval for IgA nephropathy into a full approval, a decision that came with an expanded label
- Sep 6
The CEO of Marseille based ImCheck Therapeutics on targeting butyrophilin to modulate innate and adaptive immunity
- Sep 6
Innate Pharma's Founder & CEO gives an overview of the company's programs and discusses Marseille's strengths in immunology
- Sep 5
Paris based Coave Therapeutics is conjugating ligands onto vector surfaces to improve targeting and delivery - it is attracting partner and investor interest
- Sep 5
With a partnership with Intellia already in place, France's SparingVision aims to be a world leader in gene therapies and gene editing for ocular diseases
- Sep 5
Paris based Enterome has an IO approach that is founded on learnings from how the gut interacts with the immune system
- Sep 5
Checking in with Imvax ahead of key P2b data in glioblastoma next year of its personalized treatment that is delivered via implantable biodiffusion chambers
.png){kind=logo}
.png){kind=logo}